Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

"The UK's inability to retain economic benefits of its R&D is a fatal flaw to any growth strategy," according to the document ...

The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...

Shares in Metsera shot up nearly 20% to more than $72 after news of the renewed bidding war emerged, raising its market ...

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Today, POA Pharma is headquartered in Copenhagen, with additional facilities located across the Nordics and Germany. Galen ...

Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...